<DOC>
	<DOC>NCT00505388</DOC>
	<brief_summary>This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use of Symbicort as maintenance and reliever therapy in clinical therapies</brief_summary>
	<brief_title>A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme signed and dated informed consent(ICF) for patients underage, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>asthma</keyword>
	<keyword>bronchial</keyword>
	<keyword>Symbicort</keyword>
</DOC>